NASDAQ: LNAILunai Bioworks Inc Stock
$3.20+0.11 (+3.56%)
Updated Jul 2, 2026
LNAI Price
$3.20
Fair Value Price
N/A
Market Cap
$14.51M
52 Week Low
$1.21
52 Week High
$28.80
P/E
-0.05x
P/B
-1.52x
P/S
486.57x
PEG
N/A
Dividend Yield
N/A
Revenue
$20.94k
Earnings
-$128.28M
Gross Margin
100%
Operating Margin
-609,894.27%
Profit Margin
-612,568.1%
Debt to Equity
-2.03
Operating Cash Flow
-$5M
Beta
1.16
Next Earnings
Aug 21, 2026
Ex-Dividend
N/A
Next Dividend
N/A
LNAI Overview
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LNAI's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LNAI
Ranked#354 of 463
Ranked#354 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important LNAI news, forecast changes, insider trades & much more!
LNAI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LNAI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LNAI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LNAI is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
LNAI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more LNAI due diligence checks available for Premium users.
Valuation
LNAI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.05x
Industry
17.59x
Market
8.54x
LNAI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.52x
Industry
5.6x
LNAI's financial health
Profit margin
Revenue
$20.9k
Net Income
-$2.6M
Profit Margin
-12,278.6%
LNAI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
LNAI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.9M
Liabilities
$19.4M
Debt to equity
-2.03
LNAI's short-term liabilities ($19.28M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LNAI's short-term assets ($3.73M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LNAI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LNAI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.0M
Investing
$0.0
Financing
$3.7M
LNAI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LNAI vs Biotech Stocks
Lunai Bioworks Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.